Bogle Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Bogle Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-35,646	Closed	-$4M	–	358
2020 Q2	$4M	Sell	35,646 -88,280	-71%	-$9.37M	0.67%	62
2020 Q1	$11.1M	Buy	123,926 +98,926	+396%	+$9.71M	1.16%	7
2019 Q4	$2.7M	Buy	+25,000	New	+$2.67M	0.25%	119
2019 Q1	–	Sell	-68,758	Closed	-$6.69M	–	429
2018 Q4	$6.69M	Buy	+68,758	New	+$8.13M	0.52%	79
2018 Q3	–	Sell	-113,589	Closed	-$14.1M	–	363
2018 Q2	$14.1M	Buy	+113,589	New	+$13.3M	1.02%	17
2017 Q4	–	Sell	-66,351	Closed	-$9.31M	–	383
2017 Q3	$9.31M	Buy	+66,351	New	+$9.01M	0.63%	68
2014 Q2	–	Sell	-3,900	Closed	-$593K	–	406
2014 Q1	$593K	Buy	+3,900	New	+$620K	0.04%	296

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bogle Investment Management's ALXN Position: Q3 2020 in Review

Bogle Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 35,646 shares — an estimated $4M sold.

Bogle Investment Management first reported a position in ALXN in Q1 2014 and held it in 7 quarters. The position peaked at $14.1M in Q2 2018. 707 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

Bogle Investment Management reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Bogle Investment Management sold 35,646 Alexion Pharmaceuticals shares in Q3 2020, an estimated $4M.
Bogle Investment Management first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 7 quarters.
Bogle Investment Management's Alexion Pharmaceuticals position peaked at $14.1M in Q2 2018.
707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Bogle Investment Management's 13F filing for Q3 2020, filed 12 Nov 2020.